André P. Fay

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 499 citations

Medicine, Pharmacology, Pharmacotherapy +12

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Marcella Callea, Laurence Albigès, Mamta Gupta et al. · Cancer Immunology Research · 2015 · 342 citations · Full text

Medicine, Cancer Biology, Oncology +17

PD-L1 expression in nonclear-cell renal cell carcinoma

Toni K. Choueiri, André P. Fay, Kathryn P. Gray et al. · Annals of Oncology · 2014 · 300 citations

Medicine, Cancer Biology, Oncology +13